Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials. J of Skin [Internet]. 2022 Nov. 16 [cited 2026 Mar. 9];6(6):s66. Available from: https://skin.dermsquared.com/skin/article/view/1821